Dasatinib hydrochloride is a potent tyrosine kinase inhibitor primarily indicated for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia in patients who are positive for the Philadelphia… Read more
Dasatinib hydrochloride is a potent tyrosine kinase inhibitor primarily indicated for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia in patients who are positive for the Philadelphia chromosome. By inhibiting specific kinases that regulate cell signaling pathways responsible for cancer cell proliferation, this targeted therapy plays a critical role in oncology. Analytical laboratories rely on high-quality reference standards of Dasatinib hydrochloride, alongside its related pharmacopeial and non-pharmacopeial impurities, to ensure rigorous quality control and accurate impurity profiling. The inclusion of metabolites and stable isotope-labelled compounds in this collection further supports complex method development and validation, providing essential tools for precise quantification in biological matrices. Utilizing these analytical materials facilitates regulatory compliance and helps maintain strict standards during the production and pharmacokinetic study of this pharmaceutical substance.